Curriculum Vitaes

Hideo Izawa

  (井澤 英夫)

Profile Information

Affiliation
School of Medicine Faculty of Medicine, Fujita Health University
Degree
医学博士(名古屋大学)

J-GLOBAL ID
200901029584552340
researchmap Member ID
6000001679

Research Areas

 1

Papers

 200
  • Reina Ozaki, Sadako Motoyama, Yukio Ozaki, Masayoshi Sarai, Hideki Kawai, Tevfik F. Ismail, Wakaya Fujiwara, Keiichi Miyajima, Yasuomi Nagahara, Noriya Uchida, Scot Garg, Naoyuki Kawashima, Yudai Niwa, Hidemaro Takatsu, Yu Yoshiki, Masaya Ohta, Takashi Muramatsu, Masahide Harada, Hiroyuki Naruse, Ayaka Matsui, Haruo Kamiya, Akihiko Tobe, Tsai Tsung-Ying, Yasuko Bando, Yoshinobu Onuma, Hiroshi Takahashi, Hideo Izawa, Patrick W. Serruys, Toyoaki Murohara
    International Journal of Cardiology, 421 132895-132895, Feb, 2025  
  • Yu Yoshiki, Yukio Ozaki, Mitsuru Abe, Tevfik F Ismail, Hiroshi Takahashi, Masaharu Akao, Hideki Kawai, Takashi Muramatsu, Masahide Harada, Masaya Ohta, Yosuke Hashimoto, Yuichiro Shiki, Masayuki Koshikawa, Keiichi Miyajima, Hidemaro Takatsu, Yudai Niwa, Naoyuki Kawashima, Reina Ozaki, Naotake Tsuboi, Satoshi Iimuro, Hiroshi Iwata, Ichiro Sakuma, Yoshihisa Nakagawa, Kiyoshi Hibi, Takafumi Hiro, Yoshihiro Fukumoto, Seiji Hokimoto, Katsumi Miyauchi, Hisao Ogawa, Hiroyuki Daida, Hiroaki Shimokawa, Hideo Izawa, Takeshi Kimura, Ryozo Nagai
    Journal of the American Heart Association, 14(2) e034627, Jan 21, 2025  
    BACKGROUND: The effect of worsening renal function and baseline chronic kidney disease (CKD) on outcomes in patients with chronic coronary syndrome in the setting of optimal medical therapy remains unknown. METHODS AND RESULTS: The REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) study is a prospective, multicenter, randomized trial of high-dose (pitavastatin 4 mg/day) or low-dose (pitavastatin 1 mg/day) statin therapy in 12 118 patients with chronic coronary syndrome. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or unstable angina requiring hospitalization (major adverse cardiac and cerebral events [MACCE]). CKD was defined as an estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2. WRF was defined as a decrease in eGFR ≥20% in the initial year; borderline renal function was an annual decrease of 0%<eGFR<20%, and stable renal function was no decrease. Of 12 118 patients, 4340 had baseline CKD and 7778 did not. The rate of MACCE at 5 years was significantly lower in those without (5.5%) versus with CKD (9.5%) (P<0.0001). After excluding 1247 patients who had MACCE, were censored, or missing eGFR within 1 year, 10 871 patients were included. Of these, 3885 were baseline CKD and the remaining 6986 did not have baseline CKD. Of the 10 871 patients, 577 patients had WRF, 6014 patients showed borderline renal function, and the remaining 4280 patients maintained stable renal function. In patients with CKD, WRF was an independent predictor for MACCE at 4 years as compared with stable renal function (hazard ratio [HR]: 1.67; [95% CI, 1.03-2.73; P=0.039]). In patients without CKD, borderline renal function was a significant predictor for MACCE at 4 years compared with stable renal function (HR: 1.40 [95% CI, 1.03-1.91; P=0.032]). CONCLUSIONS: Baseline CKD was an independent predictor for MACCE in patients with CCS. WRF was a significant predictor for MACCE in patients with CKD. Because borderline renal function was an independent predictor for MACCE even in patients without CKD, mild-to-moderate annual declines of eGFR should be carefully monitored (NCT01042730). REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01042730.
  • Yuji Kono, Masahiko Mukaino, Yushi Ozawa, Koji Mizutani, Yuki Senju, Takayuki Ogasawara, Masumi Yamaguchi, Takashi Muramatu, Hideo Izawa, Yohei Otaka
    Heart and vessels, 39(10) 918-919, Oct, 2024  
  • Taro Makino, Yuya Ishihara, Masahide Harada, Yoshihiro Sobue, Eiichi Watanabe, Yukio Ozaki, Hideo Izawa
    International Heart Journal, 65(5) 841-848, Sep 30, 2024  
  • Masataka Yoshinaga, Takashi Muramatsu, Masato Ishikawa, Takuo Toriya, Takashi Uwatoko, Yuji Matsuwaki, Yuko Ukai, Yohei Kobayashi, Katsuyoshi Ito, Hideaki Ota, Hideo Izawa
    Cardiovascular intervention and therapeutics, Aug 13, 2024  
    Slow-flow or no-reflow phenomenon is a common procedural complication during percutaneous coronary intervention (PCI). Given the presence of fragile plaque or thrombotic materials, we hypothesized that long-time predilatation using a perfusion balloon in conjunction with intracoronary nicorandil administration reduces the risk of slow-flow or no-reflow in patients presenting with acute coronary syndrome (ACS). Subjects were patients presenting with ACS who underwent PCI between April 2020 and April 2022. We retrospectively investigated the incidence of slow-flow or no-reflow during the procedure as well as in-hospital outcomes in comparison between the cases undergoing 3-min predilatation using a perfusion balloon in conjunction with intracoronary nicorandil administration followed by DES implantation (PB group) and those with direct stenting (DS group). Among 439 ACS patients, 36 patients in the PB group and 51 patients in the DS group were examined. Mean age was 70 years and 78.2% was male. Distal protection devices were more frequently used in the DS group than in the PB group (31.3% vs. 11.1%, p = 0.02). The incidence rate of slow-flow or no-reflow was significantly lower in the PB group than in the DS group (2.8% vs. 23.5%; p < 0.01). Six cases (11.7%) in the DS group required intra-aortic balloon pumping (IABP), while none in the PB group required (p < 0.01). In-hospital clinical outcomes did not differ between the two groups. Prolonged perfusion balloon predilatation in conjunction with intracoronary nicorandil administration was safe and feasible. This novel strategy could be an attractive alternative to conventional direct stenting for ACS patients.

Misc.

 273
  • Masataka Yoshinaga, Takashi Muramatsu, Hidetsugu Fujigaki, Kuniaki Saito, Hideo Izawa
    Fujita medical journal, 8(2) 65-66, May, 2022  
  • 神野 真司, 山田 晶, 杉本 邦彦, 中嶋 千尋, 河田 祐佳, 船戸 優佑, 山邊 小百合, 星野 直樹, 星野 芽以子, 高田 佳代子, 上田 清乃, 佐藤 嘉洋, 河合 秀樹, 谷澤 貞子, 皿井 正義, 井澤 英夫
    日本循環器学会学術集会抄録集, 86回 MPJ08-2, Mar, 2022  
  • 佐藤 嘉洋, 河合 秀樹, 星野 芽以子, 谷澤 貞子, 成瀬 寛之, 石井 潤一, 皿井 正義, 井澤 英夫
    日本循環器学会学術集会抄録集, 86回 PJ51-4, Mar, 2022  
  • 松脇 佑次, 小林 昌義, 丹羽 若菜, 良永 真隆, 村松 崇, 井澤 英夫
    脈管学, 61(Suppl.) S247-S247, Oct, 2021  
  • 河野 裕治, 小澤 祐士, 水谷 公司, 千手 佑樹, 船戸 優佑, 村松 崇, 井澤 英夫, 大高 洋平
    日本循環器病予防学会誌, 56(2) 177-177, May, 2021  
  • Ryo Yamada, Satoshi Okumura, Yuji Kono, Akane Miyazaki, Yudai Niwa, Takehiro Ito, Sayano Ueda, Tomoya Ishiguro, Masataka Yoshinaga, Wakaya Fujiwara, Mutsuharu Hayashi, Yukio Ozaki, Eiichi Saitoh, Hideo Izawa
    Fujita medical journal, 7(3) 76-82, 2021  
    OBJECTIVES: There are benefits of exercise-based cardiac rehabilitation (CR) in patients with heart failure (HF), but their underlying molecular mechanisms remain elusive. The effect of CR on the expression profile of circulating microRNAs (miRNAs), which are short noncoding RNAs that regulate posttranscriptional expression of target genes, is unknown. If miRNAs respond to changes following CR for HF, then serum profiling of miRNAs may reveal cardioprotective mechanisms of CR. METHODS: This study enrolled three hospitalized patients with progressed systolic HF and three normal volunteer controls. In patients, CR was initiated after improvement of HF, which included 2 weeks of bicycle ergometer and resistance exercises. Genome-wide expression profiling of circulating miRNAs was performed using microarrays for the patients (mean±SD age, 60.0±12.2 years) and controls (58.7±0.58 years). Circulating miRNA expression profiles were compared between patients with HF before and after CR and the controls. RESULTS: Expression levels of two miRNAs were significantly different in patients before CR compared with controls and patients after CR. The expression of hsa-miR-125b-1-3p was significantly downregulated and that of hsa-miR-1290 was significantly upregulated in patients before CR. CONCLUSIONS: When performing CR, expression of certain circulating miRNAs in patients with HF is restored to nonpathological levels. The benefits of CR for HF may result from regulation of miRNAs through multiple effects of gene expression.
  • 河合 秀樹, 皿井 正義, 加藤 靖周, 成瀬 寛之, 佐藤 嘉洋, 元山 貞子, 外山 宏, 森本 紳一郎, 井澤 英夫
    日本サルコイドーシス/肉芽腫性疾患学会雑誌, 40(サプリメント号) 61-61, Oct, 2020  
  • 河野 裕治, 山田 亮, 大高 洋平, 才藤 栄一, 井澤 英夫
    Heart View, 24(5) 454-458, May, 2020  
    <文献概要>Point 1 高齢心不全のサルコペニアは,加齢による一次性と病態進行によるカヘキシアを起因とした二次性が混在している。2 カヘキシアを併存する場合はカロリー摂取を優先し,運動強度も低強度に留めることが勧められる。3 サルコペニア単独の場合はたんぱく質の摂取と積極的な運動療法が勧められる。
  • 山田 亮, 奥村 聡, 丹羽 雄大, 宮崎 茜, 伊藤 丈浩, 上田 清乃, 石黒 智也, 良永 真隆, 藤原 稚也, 林 睦晴, 成瀬 寛之, 石井 潤一, 尾崎 行男, 井澤 英夫
    日本心臓病学会学術集会抄録, 67回 O-044, Sep, 2019  
  • 河野 裕治, 山田 亮, 上田 清乃, 青柳 陽一郎, 井澤 英夫
    Heart View, 23(7) 679-684, Jul, 2019  
    <Point>1 左室駆出率の保たれた心不全(heart failure with preserved ejection fraction:HFpEF)に対する運動療法の効果に関するエビデンスは十分ではない。2 HFpEFに対する運動療法は、運動耐容能や症状、QOLを改善する。3 HFpEFに対する運動耐容能の改善には末梢骨格筋機能の改善が寄与する。(著者抄録)
  • 河野 裕治, 井澤 英夫, 青柳 陽一郎, 山田 亮, 石黒 智也, 良永 真隆, 奥村 聡, 藤原 稚也, 林 睦晴, 才藤 栄一
    日本循環器学会学術集会抄録集, 83回 CP03-1, Mar, 2019  
  • 西村 豪人, 石井 潤一, 河合 秀樹, 村松 崇, 原田 将英, 元山 貞子, 成瀬 寛之, 渡邉 英一, 林 睦晴, 井澤 英夫, 尾崎 行男
    日本循環器学会学術集会抄録集, 83回 OJ03-2, Mar, 2019  
  • 成瀬 寛之, 石井 潤一, 西村 豪人, 大田 将也, 河合 秀樹, 村松 崇, 原田 将英, 山田 晶, 元山 貞子, 林 睦晴, 皿井 正義, 井澤 英夫, 渡邉 英一, 尾崎 行男
    日本循環器学会学術集会抄録集, 83回 OJ03-3, Mar, 2019  
  • 西村 豪人, 石井 潤一, 河合 秀樹, 村松 崇, 原田 将英, 成瀬 寛之, 元山 貞子, 渡邉 英一, 林 睦晴, 井澤 英夫, 尾崎 行男
    日本循環器学会学術集会抄録集, 83回 OJ15-4, Mar, 2019  
  • 河野 裕治, 井澤 英夫, 青柳 陽一郎, 山田 亮, 石黒 智也, 良永 真隆, 奥村 聡, 藤原 稚也, 林 睦晴, 才藤 栄一
    日本循環器学会学術集会抄録集, 83回 CP03-1, Mar, 2019  
  • 河野裕治, 山田亮, 上田清乃, 青柳陽一郎, 井澤英夫
    Heart View, 23 63-68, 2019  Invited
  • Wakaya Fujiwara, Yasuchika Kato, Mutsuharu Hayashi, Yoshinori Sugishita, Satoshi Okumura, Masataka Yoshinaga, Tomoya Ishiguro, Ryo Yamada, Sayano Ueda, Masahide Harada, Hiroyuki Naruse, Junnichi Ishii, Yukio Ozaki, Hideo Izawa
    Journal of Cardiology, 72 452-457, Dec 1, 2018  
    © 2018 Japanese College of Cardiology Background: Although cardiac sarcoidosis is associated with poor prognosis, diagnosis of the disease is challenging and the sensitivity and specificity of diagnostic modalities are limited. This study was performed to evaluate the potential of serum microRNAs (miRNAs) as diagnostic biomarkers for cardiac sarcoidosis. Methods: We performed genome-wide expression profiling for 2565 miRNAs (Human-miRNA ver.21) using peripheral blood samples from 5 patients with cardiac sarcoidosis (61 ± 9 years) and 3 healthy controls (54 ± 7 years). From this screening study, we selected 12 miRNAs that were significantly related to cardiac sarcoidosis. Next, we performed real-time polymerase chain reaction (PCR) on blood samples from 15 new patients with cardiac sarcoidosis and 4 healthy controls to quantify the expression of these 12 miRNAs. Results: In the screening study, 12 miRNAs were differentially expressed (p &lt; 0.01) in all 5 patients with cardiac sarcoidosis, showing greater fold-change values (&gt;4 or &lt;0.25) compared with the expression in the 3 healthy controls. Analysis of the real-time PCR for blood samples from the other 15 patients and 4 controls using Mann–Whitney U tests revealed that the expression of miR-126 and miR-223 was significantly higher in the patients than in the healthy individuals. However, there were no differences in the expressions of miRNA-126 and miR-223 between patients with only cardiac lesions and those with extra-cardiac lesions. Conclusions: Our results demonstrate the potential of serum miR-126 and miR-223 as new-generation biomarkers for the differential diagnosis of cardiac sarcoidosis in patients with heart failure.
  • Hiroyuki Naruse, Junnichi Ishii, Hiroshi Takahashi, Fumihiko Kitagawa, Hideto Nishimura, Hideki Kawai, Takashi Muramatsu, Masahide Harada, Akira Yamada, Sadako Motoyama, Shigeru Matsui, Mutsuharu Hayashi, Masayoshi Sarai, Eiichi Watanabe, Hideo Izawa, Yukio Ozaki
    Critical Care, 22, Aug 18, 2018  
    © 2018 The Author(s). Background: The early prediction of acute kidney injury (AKI) can facilitate timely intervention and prevent complications. We aimed to understand the predictive value of urinary liver-type fatty-acid binding protein (L-FABP) levels on admission to medical (non-surgical) cardiac intensive care units (CICUs) for AKI, both independently and in combination with serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Methods: We prospectively investigated the predictive value of L-FABP and NT-proBNP for AKI in a large, heterogeneous cohort of patients treated in medical CICUs. Baseline urinary L-FABP and serum NT-proBNP were measured on admission. AKI was diagnosed according to the Kidney Disease: Improving Global Outcomes criteria. We studied 1273 patients (mean age, 68years), among whom 46% had acute coronary syndromes, 38% had acute decompensated heart failure, 5% had arrhythmia, 3% had pulmonary hypertension, 2% had acute aortic syndrome, 2% had infective endocarditis, and 1% had Takotsubo cardiomyopathy. Results: Urinary L-FABP levels correlated with serum NT-proBNP levels (r=0.17, p&lt;0.0001). AKI occurred in 224 patients (17.6%), including 48 patients with stage 2 or 3 disease. Patients who developed AKI had higher one-week and 6-month mortality than those who did not develop AKI (p=0.0002 and p=0.003, respectively). In the multivariate logistic analysis, both L-FABP (p&lt;0.0001) and NT-proBNP (p=0.006) were independently associated with the development of AKI. Adding L-FABP and NT-proBNP to a baseline model that included established risk factors further improved reclassification (p&lt;0.001) and discrimination (p&lt;0.01) beyond that of the baseline model or any single biomarker individually. Conclusions: Urinary L-FABP and serum NT-proBNP levels on admission are independent predictors of AKI, and when used in combination, improve early prediction of AKI in patients hospitalized at medical CICUs.
  • Hiroyuki Naruse, Junnichi Ishii, Hiroshi Takahashi, Fumihiko Kitagawa, Ryuunosuke Okuyama, Hideki Kawai, Takashi Muramatsu, Masahide Harada, Akira Yamada, Sadako Motoyama, Shigeru Matsui, Mutsuharu Hayashi, Masayoshi Sarai, Eiichi Watanabe, Hideo Izawa, Yukio Ozaki
    CIRCULATION JOURNAL, 81(10) 1506-1513, Oct, 2017  
    Background: A modestly elevated circulating D-dimer level may be relevant to coronary artery disease (CAD), but its prognostic value, both independently and in combination with estimated glomerular filtration rate (eGFR), for long-term death has not been fully evaluated in stable CAD patients. Methods and Results: Baseline plasma D-dimer levels and eGFR were measured in 1,341 outpatients (mean age: 65 years) with prior myocardial infarction (MI), coronary revascularization, and/or angiographic evidence of a significant stenosis (&gt; 50%) for at least one of the major coronary arteries. Among these patients, 43% had prior MI, 47% had prior coronary revascularization, 41% had multivessel CAD, 14% had paroxysmal or persistent atrial fibrillation, 32% had diabetes, and 32% had chronic kidney disease (eGFR &lt; 60 mL/min/1.73 m2). D-dimer levels weakly correlated with eGFR (r=-0.25; P&lt; 0.0001). During a mean follow-up period of 73 months, there were 124 deaths, including 61 cardiovascular deaths. Multivariate Cox regression analysis identified D-dimer levels (P=0.001) and eGFR (P=0.006) as independent predictors of all-cause death. Adding both D-dimer and eGFR to a baseline model with established risk factors improved the net reclassification (P&lt; 0.005) and integrated discrimination improvement (P&lt; 0.05) greater than that of any single biomarker or baseline model alone. Conclusions: The combinatorial value of assessing D-dimer levels and eGFR may provide useful insight regarding stable CAD patients' long-term risk stratification.
  • Fumihiko Kitagawa, Junnichi Ishii, Shinya Hiramitsu, Hiroshi Takahashi, Ryuunosuke Okuyama, Hideki Kawai, Takashi Muramatsu, Masahide Harada, Sadako Motoyama, Hiroyuki Naruse, Shigeru Matsui, Masayoshi Sarai, Mutsuharu Hayashi, Eiichi Watanabe, Hideo Izawa, Yukio Ozaki
    HEART AND VESSELS, 32(5) 609-617, May, 2017  
    Whether trough-phase rivaroxaban concentrations provide sufficient anticoagulation needs more study. We evaluated levels of coagulation activation markers in the trough concentration phase in nonvalvular atrial fibrillation (NVAF) patients, and the correlation between these markers and rivaroxaban concentration. Fifty-five Japanese NVAF patients received 24-week rivaroxaban treatment of either 15 or 10 mg once-daily in the morning. Of these, 26 patients had no history of anticoagulant therapy (naive group) and 29 had switched from warfarin (warfarin group). D-dimer and prothrombin fragment 1 + 2 (F1 + 2) levels, and protein C activities were measured at 0 (baseline), 12 and 24 weeks of rivaroxaban treatment just before the patient's regular dosing time (trough phase). For 49 patients, D-dimer, F1 + 2, and rivaroxaban concentrations were also measured twice between 28 and 32 weeks of rivaroxaban treatment at non-trough times to achieve a range of drug concentrations for correlation analysis. For the naive group, D-dimer and F1 + 2 levels were significantly reduced (p &lt; 0.01) from baseline at 12 and 24 weeks. For the warfarin group, these values were unchanged for D-dimer but significantly increased (p &lt; 0.01) for F1 + 2. Protein C activity was unchanged in the naive group and was increased (p &lt; 0.01) in the warfarin group. Prothrombin time (r = 0.92, p &lt; 0.0001) and activated partial thromboplastin time (r = 0.54, p &lt; 0.0001) correlated with rivaroxaban concentration, but not D-dimer and F1 + 2 levels. In conclusion, rivaroxaban in the trough phase is comparable to warfarin in reducing D-dimer levels. Although trough level rivaroxaban suppresses F1 + 2 less than warfarin, the higher activities of protein C with rivaroxaban treatment compared to warfarin treatment may counterbalance this. Lack of correlation between rivaroxaban concentration and D-dimer and F1 + 2 levels suggests that trough concentrations of rivaroxaban reduce their concentrations as effectively as higher levels do.
  • Mutsuharu Hayashi, Yoshinari Yasuda, Susumu Suzuki, Manaka Tagaya, Takehiro Ito, Tomohito Kamada, Masataka Yoshinaga, Yoshinori Sugishita, Wakaya Fujiwara, Hiroatsu Yokoi, Yukio Ozaki, Hideo Izawa
    HEART AND VESSELS, 32(3) 279-286, Mar, 2017  
    Although the renin-angiotensin system (RAS) is counter-balanced by a salt-sensitive mechanism in the hypertensive state, both are reported to be up-regulated in chronic kidney disease (CKD) patients. We conducted this study to evaluate the associations among the RAS, renal function, hypertension, and atherosclerosis, as well as to identify markers for salt-sensitivity. A total of 213 pre-dialysis CKD patients with preserved cardiac function (EF &gt; 50 %) were enrolled. Their renal and cardiac biochemical markers and plasma renin activity (PRA) were measured, and echocardiography and carotid artery ultrasound were performed. Their salt intake was estimated by the NaCl excretion from a 24-h collected urine sample. The PRA was higher in patients with hypertension (p = 0.018), and had a significant negative correlation with the eGFR (r = -0.23, p = 0.0067). Importantly, the PRA had a strong negative correlation with the brain natriuretic peptide (BNP) level (r = -0.28, p = 0.017) regardless of whether the patients were being treated with RAS inhibitors. The BNP level was related to the renal functions (eGFR: p = 0.001, ACR: p = 0.009). There was a significant positive correlation between the BNP level and carotid intima-media thickness (p &lt; 0.001). A multivariate analysis revealed that older age and an excess of NaCl excretion were independent predictors of BNP elevation (p = 0.02 and 0.003, respectively). Our analysis revealed details of the counterbalance between BNP and PRA, as well as identifying that excess salt intake is a predictor of BNP elevation. These results indicate that the BNP could be a possible valuable marker for salt sensitivity, and that high salt sensitivity could facilitate atherosclerosis in CKD patients.
  • Hideo Izawa, Yuji Kohno, Wakaya Fujiwara, Mutsuharu Hayashi
    CIRCULATION JOURNAL, 81(1) 28-29, Jan, 2017  
  • 井澤英夫, 河野裕治, 粥川知子, 青柳陽一郎, 才藤栄一, 藤原稚也, 林睦晴
    現代医学, 65(2) 71-75, 2017  Invited
  • Tomohito Kamada, Mutsuharu Hayashi, Wakaya Fujiwara, Daiji Yoshikawa, Daisuke Mukaide, Yoshinori Sugishita, Masataka Yoshinaga, Takehiro Itoh, Hiroatsu Yokoi, Junichi Ishii, Eiichi Watanabe, Yukio Ozaki, Hideo Izawa
    DRUG AND CHEMICAL TOXICOLOGY, 40(1) 110-114, Jan, 2017  
    Objectives: The number of elderly patients with hypertension has been steadily increasing. However, there are limited data on the safety and efficacy of the new angiotensin type 1 receptor blocker (ARB) azilsartan in elderly patients with hypertension. We investigated the clinical efficacy and safety of azilsartan in this population. Methods: The study population comprised 56 ambulatory patients with essential hypertension. We evaluated the reduction in blood pressure and safety after 12 weeks of treatment with azilsartan in 29 hypertensive patients65 years of age (aged group) in comparison with the findings in 27 patients &lt;65 years of age (non-aged group). Results: Systolic blood pressure in the aged group declined significantly from 155 +/- 18mmHg at baseline to 138 +/- 11mmHg after 12 weeks of treatment with azilsartan, and that in the non-aged group also declined significantly from 152 +/- 20mmHg at baseline to 142 +/- 13mmHg after 12 weeks of treatment with azilsartan. There were no significant differences in the magnitude of change in blood pressures from pre-treatment to post-treatment with azilsartan between the non-aged and aged groups. There were no changes in clinical laboratory findings, including serum levels of creatinine, potassium, lipids, and other metabolic variables, after 12 weeks of treatment with azilsartan in both groups. Conclusions: Our findings suggest that azilsartan is effective in lowering blood pressure in elderly patients and may be safe. Therefore, azilsartan could be a valuable option for treating hypertension in elderly and non-elderly patients.
  • Manaka Tagaya, Daiji Yoshikawa, Yoshinori Sugishita, Fumi Yamauchi, Takehiro Ito, Tomohito Kamada, Masataka Yoshinaga, Daisuke Mukaide, Wakaya Fujiwara, Hiroatsu Yokoi, Mutsuharu Hayashi, Eiichi Watanabe, Junichi Ishii, Yukio Ozaki, Hideo Izawa
    Heart and Vessels, 31 957-962, Jun 1, 2016  
    © 2015, Springer Japan. New oral anticoagulants (NOACs) are now clinically available. However, few studies have demonstrated which patients with non-valvular atrial fibrillation (NVAF) actually receive NOACs in a clinical setting. We analyzed 182 NVAF patients who received oral anticoagulants. Clinical backgrounds and the risk of stroke, systemic embolism, and bleeding associated with oral anticoagulants were investigated. Seventy-three (40 %) patients were treated with NOACs and 109 (60 %) patients were treated with warfarin. A significantly lower mean number of bleeding risk factors was observed among the patients treated with NOACs than among those treated with warfarin (P = 0.010). Of the bleeding risk factors, NOACs were significantly less frequently prescribed in patients with a bleeding history and elderly subjects (&gt;65 years) than in those who received warfarin (P &lt; 0.001 and P = 0.029). A multivariate logistic regression analysis revealed that CHF and bleeding history were independently and significantly associated with the administration of NOACs (P = 0.047 and P = 0.003). The rate of a history of intracranial hemorrhage was comparable between the patients treated with NOACs and those treated with warfarin (P = 1.000). Significantly lower rates of a history of gastrointestinal and other minor bleeding were observed in the patients who received NOACs versus those who received warfarin (P = 0.001 and P = 0.026). NOACs were less frequently prescribed in patients with a history of bleeding, especially those with a history of gastrointestinal bleeding in a clinical setting.
  • Mutsuharu Hayashi, Tomohito Kamada, Hiroatsu Yokoi, Wakaya Fujiwara, Daiji Yoshikawa, Daisuke Mukaide, Yoshinori Sugishita, Masataka Yoshinaga, Takehiro Ito, Yukio Ozaki, Hideo Izawa
    Internal Medicine, 55 323, Feb 1, 2016  
  • Masahiro Nakatochi, Sahoko Ichihara, Ken Yamamoto, Keizo Ohnaka, Yosuke Kato, Shigeki Yokota, Akihiro Hirashiki, Keiko Naruse, Hiroyuki Asano, Hideo Izawa, Tatsuaki Matsubara, Mitsuhiro Yokota
    Diabetologia, 58 2781-2790, Dec, 2015  Peer-reviewed
  • Yoshinaga Masataka, Tagaya Manaka, Izawa Hideo, Hayashi Mutsuharu, Yokoi Hiroatsu, Fujiwara Wakaya, Yoshikawa Daiji, Mukaide Daisuke, Sugishita Yoshinori, Kamada Tomohito, Ito Takehiro
    Shinzo, 47(10) 1213-1218, 2015  
  • Tomohito Kamada, Mutsuharu Hayashi, Hiroatsu Yokoi, Wakaya Fujiwara, Daiji Yoshikawa, Daisuke Mukaide, Yoshinori Sugishita, Masataka Yoshinaga, Takehiro Ito, Yukio Ozaki, Hideo Izawa
    Internal Medicine, 54 31-35, Jan 1, 2015  
    © 2015 The Japanese Society of Internal Medicine. Takotsubo cardiomyopathy is a disorder characterized by left ventricular apical ballooning with preceding emotional and/or physical stressors. This condition is also an important differential diagnosis of acute coronary syndrome. We herein describe a case of Takotsubo cardiomyopathy, a significant clinical phenomenon, triggered by delayed-onset rhabdomyolysis following the administration of long-term statin treatment, without any preceding stressors or changes in the patient’s medical condition, in association with complaints of nonspecific muscle-related symptoms. Although an electrocardiogram showed remarkable ST-segment elevation, a careful reading of the electrocardiogram findings revealed the features of Takotsubo cardiomyopathy. Withdrawing the statin therapy improved the patient’s cardiac function.
  • Masataka Yoshinaga, Daiji Yoshikawa, Hideki Ishii, Akihiro Hirashiki, Takahiro Okumura, Aki Kubota, Shinichi Sakai, Ken Harada, Fuji Somura, Tomofumi Mizuno, Wakaya Fujiwara, Hiroatsu Yokoi, Mutsuharu Hayashi, Junichi Ishii, Yukio Ozaki, Toyoaki Murohara, Yukihiko Yoshida, Tetsuya Amano, Hideo Izawa
    International Heart Journal, 56 415-420, Jan 1, 2015  
    © 2015, International Heart Journal Association. All rights reserved. Hypertrophic cardiomyopathy (HCM) has various morphological and clinical features. A decade has passed since the previous survey of the epidemiological and clinical characteristics of Japanese HCM patients. The Aichi Hypertrophic Cardiomyopathy (AHC) Registry is based on a prospective multicenter observational study of HCM patients. The clinical characteristics of 42 ambulant HCM patients followed up for up to 5 years were investigated. The primary endpoint was major adverse cardiac events (MACE), defined as death, non-fatal stroke, admission due to congestive heart failure (CHF), or episodes of sustained ventricular tachycardia/fibrillation. The MACE-free survival during the 5-year follow-up period was 76% according to Kaplan–Meier analysis. HCM-related death occurred in 3 (7%) patients and SCD occurred in 2 (5%) patients. Additionally, 3 (7%) patients were admitted to the hospital due to CHF. Meanwhile, sustained VT was detected in one (2%) of the patients who received ICD implantation and subsequently terminated with antitachycardia pacing using an ICD. The patients with HCM exhibiting left ventricular outflow obstruction (HOCM) had a slightly lower MACE-free survival rate than those with neither HOCM nor dilated-HCM (dHCM) (71% versus 81%, log-rank P = 0.581). Furthermore, the patients with dHCM demonstrated a significantly lower MACE-free survival rate than those with neither HOCM nor dHCM (33% versus 81%, log-rank P = 0.029). In the AHC Registry targeting current Japanese HCM patients, we demonstrated that many HCM patients continue to suffer from MACE despite the development of various treatments for HCM.
  • 井澤 英夫, 山田 純生, 西垣 和彦, 宮澤 靖, 河野 裕治, 伊藤 義浩, 長田 尚彦, 平敷 安希博, 吉田 俊子, 池亀 俊美, 小林 聖典, 高橋 哲也, 森尾 裕志, 池田 久雄, 後藤 葉一, 牧田 茂, 日本心臓リハビリテーション学会心臓リハビリテーション標準プログラム策定部会
    心臓リハビリテーション, 19(2) 259-272, Jun, 2014  
  • Wakaya Fujiwara, Hideo Izawa, Gen Ukai, Hiroatsu Yokoi, Daisuke Mukaide, Kohsuke Kinoshita, Shin Ichiro Morimoto, Junichi Ishii, Yukio Ozaki, Masanori Nomura
    Heart and Vessels, 28 316-322, May 1, 2013  
    Previous studies have shown highly effective lowering of blood pressure with thiazide diuretics in combination with angiotensin receptor blockers. However, thiazide diuretics may cause the development of diabetes and abnormal lipid metabolism. Little is known as to whether dysmetabolic potential of thiazide diuretics could be neutralized when adding angiotensin receptor blockers. This study consisted of 26 patients with essential hypertension. Patients were randomized to 24 weeks of treatment with either candesartan, 12 mg monotherapy (n = 13, group A), or hydrochlorothiazide (HCTZ), 6.25 mg in combination with candesartan, 8 mg (n = 13, group B). Before and after treatment, we assessed glucose and lipid profiles including adiponectin, resistin, and active glucagon-like peptide-1 (GLP-1) levels. At baseline, there were no differences in age, body mass index, systolic blood pressure (SBP), and diastolic blood pressure (DBP), as well as plasma levels of hemoglobin A1c, insulin, low-density lipoprotein cholesterol, triglycerides, adiponectin, resistin, and active GLP-1 between the two groups. There were significant reductions in SBP (from 152 ± 10 mmHg at baseline to 134 ± 12 mmHg after treatment) and DBP (from 84 ± 5 mmHg at baseline to 71 ± 8 mmHg after treatment) in group A. There were also significant reductions in SBP (from 148 ± 10 at baseline to 128 ± 7 mmHg after treatment) and DBP (from 90 ± 9 at baseline to 74 ± 12 mmHg after treatment) in group B. There were no differences in reduction of SBP or DBP after 24 weeks of treatment between the two groups. There were no changes of the glucose and lipid profiles, including adiponectin, resistin, insulin, and active GLP-1 levels after 24 weeks of treatment in both groups. A low dose of HCTZ in combination with candesartan reduces blood pressure effectively without adverse effects on the glucose and lipid profiles. Therefore, the combination of thiazide diuretics and angiotensin receptor blockers could assist patients in achieving long-term control of blood pressure with good tolerability. © 2012 Springer.
  • Naruse H, Ishii J, Hashimoto T, Kawai T, Hattori K, Okumura M, Motoyama S, Matsui S, Tanaka I, Izawa H, Nomura M, Ozaki Y
    Circ J, 76(8) 1849-1855, Aug 2, 2012  
    Background: The incidence, risk factors, and outcome of contrast-induced acute kidney injury (CI-AKI) in 730 patients with acute coronary syndrome (ACS) undergoing emergency percutaneous coronary intervention (PCI), whose contrast volume was below maximum allowable contrast dose (MACD) was prospectively investigated. Methods and Results: MACD was defined as (5 ml×body weight [kg]/baseline creatinine [mg/dl]). CI-AKI was defined as a greater than 25% increase in creatinine from the baseline or an absolute increase of ≥0.5 mg/dl within 48 h after the procedure. CI-AKI occurred in 212 (29%) patients. Patients with CI-AKI had a higher risk for in-hospital mortality (9.4% vs. 1.5%, P&lt;0.001) and a longer stay in the coronary care unit (median, 4.0 vs. 3.0 days, P&lt;0.001) compared with those without CI-AKI. In a multivariate logistic analysis including 20 clinical variables, elevated glucose levels as variables categorized into quartiles were independently (P&lt;0.001) associated with the development of CI-AKI. In addition, this relationship was seen in both the subgroup of patients with known diabetes and that of those without known diabetes. Conclusions: CI-AKI might occur commonly and could be be associated with a more complicated clinical course in ACS patients undergoing emergency PCI whose contrast volume does not exceed MACD. Elevated pre-procedural glucose might be a powerful and independent risk factor for the development of CI-AKI in this population.
  • K. Kinoshita, W. Fujiwara, H. Yokoi, D. Mukaide, Y. Sugushita, J. Ishii, R. Shibata, T. Murohara, Y. Ozaki, H. Izawa
    EUROPEAN HEART JOURNAL, 33 614-614, Aug, 2012  
  • SUZUKI Makoto, YAMADA Sumio, SHIMIZU Yuko, KONO Yuji, HIRASHIKI Akihuro, IZAWA Hideo, MUROHARA Toyoaki
    American Journal of Physical Medicine & Rehabilitation, 91(6) 501-510, Jun, 2012  Peer-reviewed
  • Hashimoto T, Ishii J, Kitagawa F, Yamada S, Hattori K, Okumura M, Naruse H, Motoyama S, Matsui S, Tanaka I, Izawa H, Maruyama I, Nomura M, Ozaki Y
    Atherosclerosis, 221(2) 490-495, Apr 1, 2012  
    Objective: High-mobility group box 1 (HMGB1) is a damage-associated molecular pattern molecule, which suggests a potential role of this protein in the pathophysiology of acute coronary syndrome (ACS). Circulating HMGB1 has been shown to be independently associated with cardiac mortality in ST-segment elevation myocardial infarction. However, its prognostic value remains unclear in unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). Methods: HMGB1, high-sensitivity C-reactive protein (hsCRP), cardiac troponin I and B-type natriuretic peptide concentrations were measured on admission in 258 consecutive patients (mean age of 67 years) hospitalized for UA/NSTEMI within 24. h (mean, 7.4. h) of the onset of chest symptoms. Results: A total of 38 (14.7%) cardiovascular deaths, including 10 in-hospital deaths, occurred during a median follow-up period of 49 months after admission. In a stepwise Cox regression analysis including 19 well-known clinical predictors of ACS, HMGB1 [relative risk (RR) 3.24 per 10-fold increment; P=. 0.0003], cardiac troponin I (RR 1.83 per 10-fold increment, P=. 0.0007), Killip class. &gt;. 1 (RR 4.67, P=. 0.0001) and age (RR 1.05 per 1-year increment, P=. 0.03), but not hsCRP, were independently associated with cardiovascular mortality. In-hospital and cardiovascular mortality rates were higher in patients with increased HMGB1 (≥2.4. ng/mL of median value) than those without increased HMGB1 (6.3% vs. 1.5%, P=. 0.04; and 23% vs. 6.9%, P=. 0.0003). Conclusion: Circulating concentration of HMGB1 on admission may be a potential and independent predictor of cardiovascular mortality in patients hospitalized for UA/NSTEMI within 24. h of onset. © 2012 Elsevier Ireland Ltd.
  • Hisashi Umeda, Tomoko Kawai, Naoki Misumida, Tomoyuki Ota, Kazutaka Hayashi, Mitsunori Iwase, Hideo Izawa, Shigeo Sugino, Takeshi Shimizu, Yasushi Takeichi, Ryoji Ishiki, Haruo Inagaki, Yukio Ozaki, Toyoaki Murohara
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 4(4) 349-354, Aug, 2011  
    Background-Although stent fracture (SF) after sirolimus-eluting stent (SES) implantation has been recognized as one of the predisposing factors of in-stent restenosis, it remains uncertain whether SF can increase the risk of major adverse cardiac events (MACE), especially beyond 1 year after SES implantation. The aim of this study was to assess the impact of SF relative to non-SF on 4-year clinical outcomes after treatment with SES of comparable unselected lesions. Methods and Results-A total of 874 lesions in 793 patients undergoing SES implantation and subsequent angiography 6 to 9 months after index procedure were analyzed. At 6- to 9-month angiographic follow-up, SF was identified in 70 of 874 lesions (8.0%). In-stent late loss was significantly higher in SF lesions versus non-SF lesions (0.42 +/- 0.59 mm versus 0.13 +/- 0.49 mm, P &lt; 0.001), resulting in a significantly higher in-stent restenosis rate (21.4% versus 4.1%, P &lt; 0.001). At 4 years, SF versus non-SF was associated with a significantly higher MACE rate (23.2% versus 12.6%, P = 0.014), mainly driven by significantly higher target-lesion revascularization (18.8% versus 10.2%, P = 0.029) rate. Adverse effects of SF on clinical outcomes occurred mostly within the first year (17.4% versus 6.6%, P = 0.001), with similar MACE rate between 1 and 4 years (5.8% versus 5.9%, P = 0.611). No significant differences between SF versus non-SF patients were observed in the cumulative frequency of very late stent thrombosis (2.9% versus 1.4%, P = 0.281), death (0% versus 2.1%, P = 0.252), or myocardial infarction (5.8% versus 2.9%, P = 0.165). Conclusions-SF of SES was associated with higher MACE rate up to 1 year, mainly driven by higher target-lesion revascularization, whereas no significant association was evident between years 1 and 4. (Circ Cardiovasc Interv. 2011;4:349-354.)
  • Masahiro Nakatochi, Seiko Miyata, Daisuke Tanimura, Hideo Izawa, Hiroyuki Asano, Yosuke Murase, Ryuji Kato, Sahoko Ichihara, Keiko Naruse, Tatsuaki Matsubara, Hiroyuki Honda, Mitsuhiro Yokota
    Diabetes Research and Clinical Practice, 92(3) e61-65, 2011  Peer-reviewed
  • Daisuke Tanimura, Rei Shibata, Hideo Izawa, Akihiro Hirashiki, Hiroyuki Asano, Yosuke Murase, Seiko Miyata, Masahiro Nakatochi, Noriyuki Ouchi, Sahoko Ichihara, Kenji Yasui, Tsutomu Yoshida, Keiko Naruse, Tatsuaki Matsubara, Mitsuhiro Yokota
    European Journal of Human Genetics, 19(3) 262-269, 2011  Peer-reviewed
  • Ohtsuki M, Morimoto S, Izawa H, Ismail TF, Ishibashi-Ueda H, Horii T, Isomura T, Suma H, Nomura M, Hishida H, Kurahashi H, Ozaki Y
    Int J Cardiol, 145(2) 333-334, Nov 19, 2010  
  • Shuji Hashimoto, Tomoko S. Kato, Yoshiyuki Sumita, Norio Tanaka, Michitaka Sano, Hideo Izawa, Mitsuhiro Yokota, Kazuo Komamura, Kazuhiko Hashimura, Hideaki Kanzaki, Masafumi Kitakaze
    CIRCULATION, 122(21), Nov, 2010  
  • SHIMIZU Yuko, YAMADA Sumio, SUZUKI Makoto, MIYOSHI Hiroko, KONO Yuji, IZAWA Hideo, KATO Rinya, MUROHARA Toyoaki
    56(5) 459-466, Oct, 2010  Peer-reviewed
  • H. Naruse, J. Ishii, T. Hashimoto, K. Miyagishima, S. Matsui, H. Izawa, S. Hiramitsu, M. Nomura, Y. Ozaki
    EUROPEAN HEART JOURNAL, 31 669-669, Sep, 2010  
  • H. Izawa, Y. Kato, H. Yokoi, W. Fujiwara, C. Xian Wu, Y. Mizoguchi, S. Morimoto, T. Murohara, Y. Ozaki, M. Nomura
    EUROPEAN HEART JOURNAL, 31 274-274, Sep, 2010  
  • D. Tanimura, R. Shibata, H. Izawa, H. Asano, A. Hirashiki, S. Miyata, M. Nakatochi, K. Naruse, T. Matsubara, M. Yokota
    EUROPEAN HEART JOURNAL, 31 1006-1006, Sep, 2010  
  • 藤原 稚也, 井澤 英夫, 鎌田 智仁, 良永 真隆, 杉下 義倫, 木下 幸輔, 向出 大介, 横井 博厚, 野村 雅則
    日本心臓病学会誌, 5(Suppl.I) 439-439, Aug, 2010  
  • ISOBE Satoshi, OHSHIMA Satoru, UNNO Kazumasa, IZAWA Hideo, KATO Katsuhiko, NODA Akiko, HIRASHIKI Akihiro, MUROHARA Toyoaki
    J Nucl Cardiol., 17(6) 1082-1090, Apr, 2010  Peer-reviewed
    PMID: 20635229
  • Hiroyuki Asano, Hideo Izawa, Kohzo Nagata, Masahiro Nakatochi, Masakazu Kobayashi, Akihiro Hirashiki, Satoshi Shintani, Takao Nishizawa, Daisuke Tanimura, Keiko Naruse, Tatsuaki Matsubara, Toyoaki Murohara, Mitsuhiro Yokota
    Diabetologia, 53(2) 234-246, 2010  
  • A. Hirashiki, H. Izawa, T. Okumura, K. Ohshima, M. Sakakibara, H. Funahashi, M. Yokota, T. Murohara
    EUROPEAN HEART JOURNAL, 30 170-170, Sep, 2009